• Prospective, open-label, pilot study
• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines
•  N = 40–50 ‘CytoSorb’
• N = 40–50 standard care
• Primary outcome is time to resolution of vasoplegic shock